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ABSTRACT
The ‘silent killer’, hypertension, leads to heart disease, stroke, kidney failure and premature death. The 
phytoestrogen daidzein has been associated with vaso-protective action similar to oestrogen, with minimal 
side effects. To explore the vaso-protective activity of daidzein and also its effect on mean arterial pressure 
(MAP), daidzein was chronically administered in N-G-nitro-L-arginine methyl ester (L-NAME)-hypertensive 
male Wistar rats for 6 weeks. The male Wistar rats were divided into three groups, namely group-A (control), 
group-B (L-NAME-treated) and group-C (L-NAME+daidzein treated). After completion of 42 days (6 weeks) 
of daidzein treatment, MAP and vascular activity were observed in all the groups. Daidzein treatment of 
L-NAME hypertensive rats (group-C) for 6 weeks signifi cantly decreased the MAP (144 mm Hg) as compared to 
untreated-L-NAME-hypertensive rats/group-B (173.2 mm Hg), indicating the blood-pressure lowering property 
of daidzein. Also daidzein signifi cantly increased acetylcholine-induced maximal relaxations of the thoracic 
aorta isolated from daidzein-treated (Emax = 72.55 %) in comparison to untreated-L-NAME-hypertensive rats 
(Emax = 39.33 %). The results of the present study suggest that chronic administration of daidzein (0.5 mg/kg/
day, s.c.) helps to lower blood pressure, as indicated by a decrease in MAP, and also shows vaso-protective 
action, as indicated by the improvement in ACh-induced relaxation.
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Introduction 
We are in an era of a rapidly changing environment, and the factors that determine 
human health are rapid urbanization, ageing and globalization, which have resulted in the 
emergence of an unhealthy lifestyle. In recent times, a shifting of diseases has occurred 
from infectious to non-communicable diseases, such as cardio-vascular, diabetes, cancer 
and chronic lung disease, and these have now become the leading causes of mortality. 
Hypertension is one of the most important cardiovascular diseases that kills about nine 
million people every year. The disease proceeds to death without prior intimation, and is 
therefore called the “silent and invisible killer”. The global consequences of hypertension 
are heart disease, stroke, kidney failure, premature death and disability (BROWN et al., 
2007; PIERDOMENICO et al., 2009; ROY et al., 2008; SCUTERI and FERRUCCI, 2003; 
SIMKO, 2007). Life style and heredity (MENDELSOHN, 2002) also play a vital role in 
determining the occurrence of disease hypertension. 
The prevalence of hypertension is of major concern to males or post-menopausal 
females. With advancements in science it has become clear that oestrogen improves 
endothelial function (MENDELSOHN, 2002; KOH, 2002). Various publications have 
shown the vaso-protective effect of oestrogen by diverse mechanisms (SCUTERI and 
FERRUCCI, 2003). Oestrogen improves endothelial function by increasing eNOS-
levels (MENDELSOHN, 2002; KOH, 2002) but may participate in the development of 
breast and endometrial cancer in women, and undesirable reproductive function in men. 
To circumvent these drawbacks, oestrogen alternatives have been sought, resulting in 
the development of plant derived phytoestrogens. Phytoestrogens are classifi ed as 
isofl avones, coumestans, and lignans, that are widely distributed in soyabeans, oil seeds 
and vegetables (PEETERS et al., 2003). Structurally similar to oestradiol, soy contains 
phytoestrogens, such as genistein, daidzein, biochanin-A (DOUGLAS et al., 2006). 
Soy protein is phytoestrogen rich (LISSIN and COOKE, 2000) and populations that 
consume soy products had a lower incidence of cardiovascular disease (ANTHONY et 
al., 1996; NESTLE 2003). The phytoestrogen daidzein was included in the present study 
because of the low incidence of side effects and also because it possesses oestrogen-
like vaso-protective action (PEETERS et al., 2003; NESTLE, 2003; LICHTENSTEIN, 1998; 
NASCIMENTO et al., 1999; PARK et al., 2005; PENG et al., 1996; WOODMAN and MISSEN, 
2004). Daidzein mimics the ability of oestradiol and improves endothelium-dependent-
relaxation in ovarioectomized rats (SQUADRITO et al., 2000). Also it does not signifi cantly 
affect reproductive tissues in males (MITCHELL et al., 2001) and interestingly it does 
not show the carcinogenic potential of oestrogen (WOODMAN and MISSEN, 2004). Few 
scientifi c reports are available on daidzein that explore its vasoprotective potency and 
importantly its effect on blood pressure, especially in an L-NAME-hypertensive model. 
To investigate the activity of daidzein on the thoracic aorta and blood pressure, daidzein 
was chronically administered to L-NAME-hypertensive-male-Wistar-rats.
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Materials and methods
Animals and experiment layout. The L-NAME model of hypertension is a well-
established experimental model of hypertension. Healthy adult male-Wistar-rats, 
weighing 150-200 g, were housed in a well-ventilated animal house, with an alternate 12 
hour light and dark-cycle. The experiment was conducted as per the Institutional Animal 
Ethics Committee guidelines. After acclimatization, the male-Wistar-rats were divided 
into three groups, namely: the control/group-A, the L-NAME-hypertensive/group-B and 
the daidzein-treated L-NAME-hypertensive/group-C rats. The group-A rats were given 
drinking water ad libitum orally and normal-saline subcutaneously daily for 42 days. 
The rats of group-B were treated with L-NAME after it was dissolved in drinking water 
at a dosage of 50 mg/kg daily orally for 42 days. Also normal saline was administered 
subcutaneously for the same 42 day period in group-B rats. The group-C rats were 
chronically treated using L-NAME-hydrochloride at the same dose and route as group-B, 
and additionally daidzein was administered after it was dissolved in normal-saline at a 
dosage of 0.5 mg/kg/day subcutaneously for 42 days. 
Pressure measurement and isometric-tension-recording. After 6-weeks (42-days) 
of the study, the rats were anaesthetized with pentobarbital sodium (60 mg/kg, intra-
peritoneally), in order to measure mean arterial pressure (MAP) by an invasive-method 
using a transducer (Model MLT0380/D, AD Instrument). The MAP of the rats was measured 
after exposing the carotid artery of the anaesthetized rats. The exposed carotid artery was 
nicked under a microscope and cannulised. To read arterial pressure, the carotid artery 
was connected to the AD Instrument transducer and attached to a personal computer using 
the software program Lab-Chart v6.1.3 (Powerlab, AD Instruments, Australia). After 
completion of blood pressure monitoring of the rats in all the experimental groups, the 
thoracic aorta was isolated and kept in cold Modifi ed-Krebs-Henseleit solution (MKHS, 
4 ºC) for further study of vascular activity in an organ bath (KANDASAMY et al., 2011). 
Aortic-rings of 3-4 mm length were mounted between two hooks of 37-gauge stainless 
steel wire under a resting tension of 1.5 g in a thermostatically controlled (37 ºC ± 0.1 ºC) 
organ-bath (UGO-Basile, Italy) of 10-mL capacity, containing MKHS supplying medical 
gas in bubbled form (74 % N2+21 % O2+5 % CO2). After an hour equilibration period, 
the aortic rings were contracted with high potassium-chloride (80 mM)-depolarizing 
solution to check the tissue viability, and they were also used as a reference to compare 
phenylephrine contraction. After attainment of the maximum-contraction-plateau 
produced by potassium chloride, the effect was washed with MKHS. Once the baseline 
was reached, the arterial rings were again contracted with vasoconstrictor-phenylephrine 
with an increment of 0.5 log units to see the cumulative effect. To evaluate the effect of 
chronically administered daidzein on vascular function, aortic rings from all the groups 
were relaxed using acetylcholine (ACh)/sodium-nitroprusside (SNP).
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Statistical analysis. Vascular activity (contraction & relaxation) in the form of Emax 
(maximal response) and EC50/pD2 (the concentration producing 50 % of the maximal 
response) were analyzed by nonlinear regression analysis (sigmoidal dose response with 
variable-slope) using Graph Pad Prism version 4.00 (San Diego, California, USA). Data 
were analyzed using the Student-Newman-Keuls method for multiple group analysis. 
Concentration-dependent agonist response data were analyzed by two-way ANOVA, 
followed by the Bonferroni post-hoc test. Differences in values were considered 
statistically signifi cant at P<0.05 (SNEDECOR and COCHRAN, 1989).
Results
Effects of chronic-daidzein treatment on Mean Arterial Pressure of L-NAME 
hypertensive rats. Chronic daidzein treatment signifi cantly (P<0.05) decreased the MAP 
(144.50 ± 7.15 mm Hg, n = 6) of L-NAME-hypertensive Group C rats in comparison 
to untreated-L-NAME-hypertensive rats of group-B (173.20 ± 4.95 mm Hg, n = 10). 
Although daidzein ameliorated the MAP of group-C rats, the arterial pressure was still 
higher (Fig. 1) than the control rats of group-A (117.20 ± 3.10 mm Hg, n = 8). 
Fig. 1. Effects of chronic daidzein-treatment (0.5 mg/kg s.c.) on mean arterial pressure of 
L-NAME hypertensive rats. 
Different alphabet/superscript signifi es a signifi cant variance between different groups at P<0.05
Effects of chronic-daidzein treatment on phenylephrine-induced contraction of 
thoracic-aorta isolated from daidzein-treated-L-NAME hypertensive rats. Phenylephrine 
(1 nM-10 μM) was added cumulatively, with an increment of 0.5 log unit, to produce 
contraction of aortic rings isolated from different groups of rats (Fig. 2 and 3). A signifi cant 
(P<0.05) increase in maximal contraction to phenylephrine was found in aortic-rings of 
L-NAME-hypertensive rats of group-B (Emax = 1.05 ± 0.02 g, n = 9) in comparison to 
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control rats (Emax = 0.90 ± 0.03 g, n = 8). In daidzein-treated L-NAME-hypertensive rats 
of group-C, no change in potency or maximal contraction response to phenylephrine (pD2 
= 6.92 ± 0.07, n = 9; Emax = 1.07 ± 0.03 g, n = 9) was found in comparison to L-NAME-
hypertensive rats of group-B (pD2 = 6.95 ± 0.06, n = 9; Emax = 1.05 ± 0.02 g, n = 9).
Fig. 2. Tracing showing the effect of chronic daidzein-treatment on Phenylephrine-induced 
contraction of thoracic-aorta isolated from L-NAME-hypertensive rats
 
Fig. 3. Effects of chronic daidzein-treatment on Phenylephrine-induced contraction of thoracic-
aorta isolated from L-NAME-hypertensive rats. 
*L-NAME treated hypertensive rats vary signifi cantly in comparison to Control rats at P<0.05
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Fig. 4. Tracing showing the effect of chronic daidzein-treatment on % relaxation to ACh-elicited 
on phenylephrine-precontracted thoracic-aorta isolated from L-NAME-hypertensive rats
Fig. 5. Effects of chronic daidzein-treatment on % relaxation to ACh-elicited on phenylephrine-
precontracted thoracic-aorta isolated from L-NAME-hypertensive rats. 
*L-NAME hypertensive rats vary signifi cantly in comparison to Control at P<0.05
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Fig. 6. Tracing showing the effect of chronic daidzein treatment on % relaxation to SNP-elicited 
on phenylephrine-precontracted thoracic-aorta isolated from L-NAME-hypertensive rats
Fig. 7. Effects of chronic daidzein-treatment on % relaxation to SNP-elicited on phenylephrine-
precontracted thoracic aorta isolated from L-NAME hypertensive rats. 
*L-NAME hypertensive rats vary signifi cantly in comparison to Control at P<0.05 
#L-NAME+Daidzein group rats vary signifi cantly in comparison to L-NAME hypertensive rats at P<0.05
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Effects of chronic-daidzein treatment on % relaxation to ACh elicited on 
phenylephrine-pre-contracted thoracic-aorta isolated from L-NAME hypertensive 
rats. ACh (1 nM-10 μM) was added cumulatively to produce concentration-dependent 
relaxation of phenylephrine-pre-contracted aortic-rings, isolated from different groups 
(Fig. 4 and 5). A signifi cant (P<0.05) decrease in maximal relaxation to ACh was found 
in the aortic rings isolated from L-NAME-hypertensive rats of group-B (Emax = 39.33 ± 
1.33 %, n = 8) in comparison to control rats (Emax = 104.9 ± 1.07 %, n = 8). Daidzein 
treatment signifi cantly increased the ACh-induced maximal-relaxations of the aortic-
rings of daidzein-treated-L-NAME-hypertensive rats of group-C (Emax = 72.55 ± 4.0 %, n 
= 8) in comparison to L-NAME rats of group-B (Emax = 39.33 ± 1.23 %, n = 8). 
Effects of chronic-daidzein treatment on % relaxation to SNP elicited on 
phenylephrine-pre-contracted thoracic-aorta isolated from L-NAME hypertensive rats. 
Sodium nitroprusside (0.1 nM-10 μM) was added cumulatively to evaluate the changes 
in relaxation of phenylephrine-pre-contracted aortic-rings isolated from different groups 
(Fig. 6 and 7). A signifi cant (P<0.05) increase of vasodilatory potency of SNP (pD2 = 8.46 
± 0.05, n = 6) was found in the aortic rings of L-NAME-hypertensive rats of group-B in 
comparison to control rats (pD2 = 7.67 ± 0.05, n = 5). Daidzein treatment signifi cantly 
decreased the vasodilator potency of SNP (pD2 8.11 ± 0.05, n = 8) in the aortic-rings of 
group-C rats in comparison to L-NAME-hypertensive rats of group-B (pD2 8.46 ± 0.05; 
n = 6). However no change in maximal relaxation response to SNP was found between 
group-A, B and C (Control, Emax = 105.1 ± 1.85 %, n = 5; L-NAME, Emax = 104.8 ± 1.36 
%, n = 6 and L-NAME+daidzein, Emax = 103.70 ± 1.32 %, n = 8). 
Fig. 8. Effects of chronic daidzein-treatment on high-concentration of potassium (80 mM)-
induced contraction of thoracic aorta isolated from L-NAME-hypertensive rats 
Different alphabet/superscript signifi es a signifi cant variance between different groups at P<0.05
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Effects of chronic-daidzein treatment on high-concentration potassium (80 mM)-
induced contraction of thoracic aorta isolated from L-NAME hypertensive rats. Fig. 8 
shows the effect of chronic daidzein-treatment on high concentration potassium-induced 
(80 mM) contraction of aortic-rings isolated from different groups. Daidzein treatment 
signifi cantly (P<0.05) decreased the potassium-induced-contraction of the thoracic-aorta 
of group-C (1.26 ± 0.13 g, n = 12) in comparison to the L-NAME-hypertensive rats of 
group-B (1.78 ± 0.10 g, n = 9).
Discussion
Daidzein treatment for 42 days signifi cantly decreased the MAP of L-NAME 
hypertensive rats of group-C. CAO et al. (2006) reported that daidzein-sulphate at 20 and 
40 mg/kg as a single or multiple oral dose, decreased the blood pressure in spontaneous 
hypertension rats. In the present experiment, the signifi cant decrease in MAP of the 
daidzein-treated L-NAME-hypertensive rats may be because of the improvement of 
endothelial function mediated through the generation of nitric-oxide, as indicated by 
improvement in the relaxation of aortic rings to ACh (Fig. 4 and 5). Similar scientifi c 
reports have disclosed that daidzein improves the nitric oxide activity of blood vessels 
(MENDELSOHN, 2002; MISHRA et al., 2000; WOODMAN et al., 2004). The decreased MAP 
did not reach the level observed in the control rats. It would be of interest to determine 
whether increasing the dose or length of treatment with daidzein can completely prevent 
the effect of L-NAME.
In the present study it was observed that chronic L-NAME treatment potentiates 
the vasoconstrictor activity of phenylephrine. The increase in phenylephrine-induced 
contraction noted in L-NAME-hypertensive rats of group-B may be due to the decrease 
in basal nitric-oxide levels, infl uencing the vasodilator tone and the resulting increase 
in vasoconstrictor potency (DENNINGER and MARLETTA, 1999; FURCHGOTT and 
ZAWADZKI, 1980a; FURCHGOTT and ZAWADZKI, 1980b). 
Nitric-oxide is one of the key constituents of vascular endothelium participating in 
relaxing the blood-vessels (VANHOUTTE and MILLER, 1985). Vascular relaxation also 
depends on the type of blood vessels and mediators. Decrease in NO-level/bioavailability 
may lead to cardiovascular diseases such as hypertension. In the present experiment, 
a marked increase in ACh induced vascular relaxation of the thoracic aorta was found 
in daidzein-treated L-NAME-hypertensive rats, as compared to L-NAME-hypertensive 
rats, which indicates the contribution of daidzein to improving endothelial function. 
WOODMAN and BOUJAOUDE, (2004) also reported a signifi cant increase in sensitivity 
and maximal-response to ACh in aortic-rings of daidzein-treated rats, in comparison to 
vehicle-treated. Many scientifi c reports reveal that daidzein improves vascular function, 
primarily or partly through generation of nitric oxide, along with the generation of other 
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mediators such as EDHF, depending upon the type of blood vessels or the decrease of free 
radical generation, since free radicals scavenge nitric oxide (PARK et al., 2005; MISHRA et 
al., 2000; WOODMAN et al., 2004; CAI and HARRISON, 2000; HUANG et al., 2000; MAHN 
et al., 2005; TAYLOR et al., 2004; VERA et al., 2005). 
A signifi cant increase in vasodilator potency (pD2) of SNP was found in the 
thoracic aorta of L-NAME-hypertensive rats compared to the control and daidzein-
treated L-NAME-hypertensive rats. The change in (L-NAME-hypertensive rat) vascular 
sensitivity to SNP may be due to the increase in sensitivity to SNP. An increase of vascular 
sensitivity to SNP may be mediated through L-NAME by inhibiting vascular nitric oxide 
synthesis, or it may inhibit eNOS, or development of vascular super-sensitization to SNP 
through sensitization of sGC to NO (ROY et al., 2008; GUPTA et al., 2008; MONCADA et 
al., 1992). 
A non-signifi cant change in maximal relaxation (Emax) of the aortic-rings to SNP was 
found in all groups of rats. Similarly, VERA et al. (2005) and WOODMAN and BOUJAOUDE, 
(2004) reported a non-signifi cant change of SNP-induced relaxation of aortic-rings isolated 
from spontaneous-hypertensive rats and diadzein-treated control rats, respectively. There 
was no signifi cant change in Emax value was found, perhaps because isofl avones or 
17-β-estradiol may not participate in improving nitric-oxide-induced sensitivity (VERA 
et al., 2005) but rather act as NO donors. 
To check the tissue viability of thoracic aorta, a high potassium (80 mM)-depolarising 
solution was used. Daidzein treatment signifi cantly decreases the potassium-chloride 
(80 mM) induced contraction of aortic-rings isolated from daidzein treated L-NAME-
hypertensive rats, compared to L-NAME-hypertensive rats. Similarly, CAO et al. (2006) 
reported that daidzein decreases the contractile response induced by potassium chloride, 
and a decrease in contractile response may be accomplished by reducing extracellular 
calcium-dependent contraction.
The results of the present study suggest that chronic administration of L-NAME 
to male Wistar-rats produces signifi cant changes in thoracic aorta vascular activity. An 
increase of sensitivity to phenylephrine and SNP were found, followed by suppression 
of ACh-induced dilatation of the thoracic aorta isolated from L-NAME hypertensive 
rats. An interesting fi nding of the study was that, with chronic administration of daidzein 
together with L-NAME, daidzein was able to reduce the power of L-NAME, to develop 
MAP to the level found in hypertensive rats treated with L-NAME alone. Also daidzein 
improves the ACh-induced relaxation of the thoracic aorta, indicating the ameliorative 
action of daidzein on vascular activity.
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SAŽETAK
Hipertenzija kao „tihi ubojica“ dovodi do bolesti srca, moždanog udara, zatajivanja bubrega i prerane 
smrti. Fitoestrogen daidzein, slično kao i estrogen, djeluje zaštitno na krvne žile uz minimalne popratne učinke. 
S ciljem istraživanja zaštite krvnih žila, te učinka na krvni tlak (srednji arterijski tlak - SAT), daidzein je tijekom 
6 tjedana bio primjenjivan Wistar štakorima s L-NAME - hipertenzijom. Štakori su bili podijeljeni u tri skupine: 
skupina A (kontrola), skupina B (L-NAME liječena) i skupina C (L-NAME + liječena daidzeinom). Nakon 
42 dana liječenja u svim je skupinama bila analizirana funkcija krvnih žila i SAT. Liječenje štakora oboljelih 
od L-NAME hipertenzije (skupina C) daidzeinom dovelo je do signifi kantnog sniženja srednjega arterijskog 
tlaka (144 mm Hg) u usporedbi s neliječenim oboljelim štakorima iz skupine B (173,2 mm Hg). Navedeno 
pokazuje učinke daidzeina na snižavanje krvnog tlaka. Osim toga, daidzein dovodi do signifi kantnog povećanja 
maksimalne relaksacije torakalnog dijela aorte izazvane acetilkolinom. To pokazuju vrijednosti u skupini 
štakora liječenih daidzeinom (Emaks= 72,55 %), u usporedbi sa skupinom neliječenih štakora (Emaks= 39,33 %). 
Rezultati istraživanja potvrđuju da trajna primjena daidzeina (0,5 mg/kg/dan s.c.) pomaže snižavanju krvnog 
tlaka, na što upućuje njegova smanjena arterijska vrijednost. Osim toga, opisana primjena daidzeina djeluje 
zaštitno na krvne žile, jer poboljšava njihovu relaksaciju izazvanu acetilkolinom. 
Ključne riječi: hipertenzija, daidzein, krvni tlak, funkcije krvnih žila, štakori________________________________________________________________________________________
